A synthetic carrier for delivering at least one biologically active component to an organism utilizing a synthetically assembled peptide which may be linked to a resin.

A synthetic multiphosphorylated peptide derived from the τ protein of the paired helical filaments is described.

The monoclonal antibody is prepared against a synthetic peptide having the Sequence ID No. 1.

Provided is a synthetic peptide derived from PEDF, which has 20-39 amino acid residues.

This invention relates generally to a synthetic peptide, called LA-1, and to related peptides.

The present invention further comtemplates a vaccine comprising the synthetic peptide and a method for vaccinating human subjects against streptococcal infection.

The synthetic peptide may also contain a T cell epitope.

They may also comprise, co-entrapped or covalently linked in the same liposome, a synthetic peptide and an adjuvant which potentiates the immunogenicity of the peptide.

It is synthetic peptide made from botulinum toxin.

The immune response to the synthetic peptide is sufficient to treat the selected subject for the infectious disease.

Stable, pharmaceutical compositions including a synthetic motilin-like peptide in a buffered solution are disclosed.

The inhibitors contain each as the active ingredient a synthetic peptide having the same amino acid sequence as that of the P2 peptide or compounds analogous to the P2 peptide.

Also provided are pharmaceutical compositions containing the synthetic peptide and the use thereof.

Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20–39 amino acid residues.

A synthetic peptide capable of producing an immunological response to C. trachomatis in a vertebrate is disclosed.